Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Dyadic International, Inc.NASDAQ: DYAI

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns positive

Q1 FY2026 gross profit was $319.12K, compared with -$114.56K a year earlier. Trailing-twelve-month gross profit was $929.95K.

Context

  • Gross profit amounted to 88.3% of revenue in FY2025, up 22.4 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $319.12K or moves back toward the trailing-twelve-month quarterly average of $232.49K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$319.12K+314.3% QoQ
Last fiscal yearDec 2025
-$1.09M-147.3% YoY
LTMMar 2026
$929.95K-53.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+378.6%——
1 year-147.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(1.09M) USD
Year-over-year change
-147.3%

Gross Profit vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -53.4% is the 4th highest of 5, against a peer median of -4.5%.
  • Gross profit amounts to 31.3% of revenue for DYAI, versus a peer median of 78.7%.
DYAI Competitors
Gross Profit for DYAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$20.19M USD-48.5%—76.0%
ATHEAlterity Therapeutics LimitedFY2025A$5.31M AUD+39.6%+3.7%97.7%
RNXTRenovoRx, Inc.LTM Mar 2026$1.17M USD+702.7%—78.7%
DYAIDyadic International, Inc.LTM Mar 2026$929.95K USD-53.4%—31.3%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 USD———
PYPDPolyPid Ltd.LTM Mar 2026$0 USD———
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 USD———
VERUVeru Inc.LTM Mar 2026-$86.1K USD-102.1%——
Peer median (excluding DYAI) —-4.5%+3.7%78.7%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.